

Insomnia Market Overview: Market Trends, Strategies, And Opportunities

The Business Research Company has updated its global market reports with latest data for 2024 and projections up to 2033

LONDON, GREATER LONDON, UK, July 4, 2024 /EINPresswire.com/ -- The global insomnia market size is projected to grow from \$4.72 billion in 2023 to \$4.97 billion in 2024, at a



compound annual growth rate (CAGR) of 5.2%. This market growth is driven by factors such as increased stress levels, the prevalence of mental health conditions, shift work, irregular work hours, increased awareness and diagnosis, and high consumption of stimulants. The market is expected to reach \$6.09 billion by 2028, maintaining the same CAGR of 5.2%. This growth can be



You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs" The Business Research Company attributed to the global health crisis impact, increasing awareness of sleep hygiene, emphasis on mental health and wellness, government initiatives for sleep health, and the influence of social determinants.

Surge in Work-Related Stress Drives Market Growth The surge in work-related stress is expected to propel the growth of the insomnia market going forward. Work-

related stress refers to harmful emotional and physical responses that occur when work demands and pressures do not match the worker's resources, capabilities, or knowledge. Job stress can lead to poor health, including insomnia. Depending on the severity of insomnia, patients are treated with drugs or cognitive-behavioral therapies, among others. Thus, the surge in work-related stress is boosting sales in the insomnia market. For instance, in October 2021, according to a survey of 1,500 US employees conducted by the American Psychology Association, approximately 59% of respondents were experiencing work-related stress in 2021. Furthermore, in November 2022, according to the US Bureau of Labor Statistics, the total rate of injuries increased in 2021 to 2.3 cases per 100 full-time equivalent workers, up from 2.2 cases in 2020. Therefore, the surge in work-related stress is driving the growth of the insomnia market.

Explore comprehensive insights into the global insomnia market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=12120&type=smp

Major Players and Market Trends

Major companies operating in the insomnia market include Pfizer Inc., Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Viatris Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Eisai Co. Ltd., UCLA Health Insomnia Clinic, Jazz Pharmaceuticals PLC, Aurobindo Pharma Limited, Purdue Pharma LP, Cipla Inc., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Lupin Limited, Mallinckrodt Pharmaceuticals Plc., Fisher & Paykel Healthcare Corporation Limited, ResMed Inc., Sunovion Pharmaceuticals Inc., Casper Sleep Inc., Biocodex Inc., Vanda Pharmaceuticals Inc., Pernix Therapeutics Holdings Inc., SleepScore Labs, Alpha-Stim, Neurim Pharmaceuticals Ltd., and NightWare Inc.

Trends in the Insomnia Market

Major companies in the insomnia market are developing new products such as zaleplon-based insomnia drugs to gain a competitive edge. Zaleplon is a non-benzodiazepine sedative-hypnotic medication used for the short-term treatment of insomnia. For instance, in April 2023, Bukwang Pharm Co Ltd., a South Korea-based pharmaceutical company, launched Zaledeep Cap., the first insomnia treatment in South Korea utilizing zaleplon as its main ingredient. Zaleplon, a non-benzodiazepine drug with FDA approval for treating insomnia, is known for its rapid onset of action, short half-life, and minimal impact on daily activities. With increasing insomnia cases in modern society, the launch of Zaledeep Cap. is expected to provide a new and effective treatment option, aiming to enhance sleep quality and overall well-being for individuals suffering from insomnia.

Segments:

- Therapy Type: Non-Pharmacological Therapy, Pharmacological Therapy
- Drug Class: Anti-Depressants, Melatonin Antagonist, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, Other Drug Classes
- Route Of Administration: Oral, Parenteral, Other Route Of Administration
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Geographical Insights: North America Leading the Market

North America was the largest region in the insomnia market in 2023. The regions covered in the insomnia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Make your report purchase here and explore the whole industry's data as well https://www.thebusinessresearchcompany.com/report/insomnia-global-market-report

<u>Insomnia Global Market Report 2024</u> from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America,

USA, South America, Middle East and Africa.

• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Insomnia Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on insomnia market size, insomnia market drivers and trends, insomnia market major players, competitors' revenues, market positioning, and market growth across geographies. The insomnia market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Aromatherapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/aromatherapy-global-market-report

Sleeping Aids Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/sleeping-aids-global-market-report

Benzodiazepine Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/benzodiazepine-drugs-global-market-report

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708 Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook X LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/725142716

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.